What are nitrates and should we be worried about our tap water?
A number of its treatment sites take raw water from rivers - including the Nar, Wensum and Wissey in Norfolk - which is then treated and distributed to customers.
However, the Drinking Water Inspectorate (DWI) has identified seven sites at increasing risk of breaching nitrate levels, which would constitute a potential danger to human health.
How is drinking water regulated?
Nitrate removal is part of the process for treating water to make it compliant with regulations, which have been laid out by the DWI.
The first legal standard for nitrate was set in 1980 and the current drinking standard is 50mg/L.
Since the 1990s, water companies have been required to take remedial action when there is a risk of not meeting this standard.
Where do nitrates come from?
Nitrate is a compound formed from nitrogen and oxygen, and is found in surface water and groundwater where fertilisers have been used on the land.
Rainfall is said to wash nitrate out of the soil, which then runs into lakes, rivers and streams.
Anglian Water said excess nitrate in the environment was a consequence of modernisation and intensification of agriculture during and after World War Two.
Due to the slow travel time of nitrate from the soil surface to groundwater sources, nitrate concentrations recorded today are a result of historical land management.
The company warned stricter rules on nitrate limits would further restrict fertiliser use, potentially lowering crop yields and impacting British food security.
What are the health implications?
Downham Market GP and West Norfolk Independent councillor Dr Pallavi Devulapalli believes it is "extremely unlikely" the nitrate levels could cause a risk to public health.
She said: "Nitrates can get into our bloodstream if we drink water that contains too much of them, and that can result in methaemoglobinaemia, which is essentially slightly blue blood, reducing the capacity of the blood to carry oxygen around the body.
"They did precautionary tests and found there was a potential for nitrate contamination and were putting measures in place to stop it happening."
The DWI said this health condition occurred when nitrate intake was "very high".
The last recorded case of methaemoglobinaemia in the United Kingdom was in the 1950s.
What is Anglian Water proposing to do?
Anglian Water's business plan states it is going to invest almost £50m into its seven existing water treatment sites in Marham, Congham, Ryston, Houghton St Giles, Ringstead, Lyng Forge and North Pickenham.
Work on the sites is expected to be completed by 2029.
The water company said it had seen rising nitrate levels in raw water prior to treatment and saw the improvements as a way of being able to proactively maintain its current compliance in treated water.
It said: "We're working with landowners on long-term solutions to reduce nitrates at the source, but at the same time we're proactively investing in new solutions to remove nitrates through our treatment processes.
"This investment is all about acting early to ensure we keep ahead of emerging challenges so we can continue to keep nitrate levels in drinking water within safe limits."
Is our tap water safe to drink?
The DWI says water companies are required to monitor their sources for nitrate and take action where levels are increasing.
It said: "In this case, Anglian Water identified rising nitrate trends and, as part of its business plan, proposed an improvement scheme to manage the risk.
"This is a proactive measure and does not indicate that drinking water is currently unsafe. Notices issued through the periodic review process are intended to ensure supplies remain safe and compliant over the long term."
It said breaches must be reported so it could be assessed whether public health had been protected and if the company had met its legal duties.
Anglian Water said: "We closely monitor the quality of our drinking water, and the treated water we supply continues to meet all drinking water quality standards."
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Failing water sector needs stronger regulation, says damning review
'Cool data centres with treated sewage' - water firm
'Our paddleboards come out brown, it's disgusting'
Related internet links
Anglian Water
Drinking Water Inspectorate
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer
Accomplished biopharma executive brings nearly 25 years of experience in business development, capital formation, and enterprise strategy to this role NORFOLK, Va., July 28, 2025--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced the appointment of Ellen Lubman, MBA as Chief Business Officer. In this role, Ms. Lubman will oversee business development, capital formation and corporate strategy. "Ellen is a highly respected executive with a strong track record of building partnerships, raising capital, and developing successful corporate strategies for biotech and pharmaceutical companies," said David Marek, Chief Executive Officer of ReAlta. "We are excited to welcome Ellen at such a pivotal moment for our business with all three clinical programs reading out this year. Her deep strategic and transactional expertise strengthens our team, and she will play a key leadership role as we forge partnerships with pharmaceutical companies and investors alike to advance our transformative therapies for patients across numerous severe inflammatory diseases with high unmet need." "I am thrilled to join ReAlta and build on the company's accomplishments in developing the EPICC platform and its lead asset pegtarazimod, which has the potential for clarity this year on a path to approval in hypoxic ischemic encephalopathy (HIE), a devastating disease where no pharmacologic treatment exists," said Ms. Lubman. "It is a privilege to contribute to the advancement of this differentiated approach to support the delivery of innovative therapies treating neuroinflammation in newborns with HIE, acute graft-versus-host disease (aGvHD), and acute Chronic Obstructive Pulmonary Disease (COPD)." Ms. Lubman brings seasoned leadership and broad experience across small to large-cap private and public biopharmaceutical companies, with a strong track record in strategic, transactional, and operational roles to ReAlta. She joins ReAlta from Werewolf Therapeutics where she was Chief Business Officer, ushering the company through multiple financings, including an Initial Public Offering, as well as business development transactions. Prior to Werewolf, she was Chief Business Officer of Impel Pharmaceuticals and Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company's diverse pipeline of therapeutics in a variety of disease areas. Ms. Lubman has held numerous other executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. She serves on the Board of Directors of Reunion Neuroscience and Cytovation ASA and is a Strategic Advisor to Two Bear Capital. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. About ReAlta Life Sciences ReAlta Life Sciences, Inc. is a clinical mid-stage biopharmaceutical company dedicated to addressing life threatening rare and acute inflammatory diseases by rebalancing the inflammatory response. The Company's EPICC peptide platform leverages discoveries from the human astrovirus (HAstV-1), which uniquely inhibits components of the innate immune system. ReAlta's therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs). The Company's lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that causes brain damage and high mortality in oxygen-deprived newborns; Orphan Drug Designation by the European Medicines Agency for HIE; FDA Orphan Drug and Fast Track Designations for acute graft-versus-host disease (aGvHD) associated with bone marrow and stem cell transplants; and FDA IND clearance for acute exacerbations of chronic obstructive pulmonary disease (COPD). Founded in 2018, ReAlta operates in Norfolk, Virginia and Aguadilla, Puerto Rico. For more information, please visit View source version on Contacts Investors John RickmanChief Financial Officerjrickman@ Media Harrison WongICR HealthcareReAltaPR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Older Breast Cancer Patients Face Inconsistent Bone Care
TOPLINE: Bone health management for older women with breast cancer receiving aromatase inhibitors (AIs) varied substantially across five UK hospitals. Despite the higher risk for fractures, women older than 80 years were less likely to receive DEXA scans or bisphosphonates, highlighting the urgent need for standardised bone monitoring and treatment in frail older patients. METHODOLOGY: This secondary analysis of the multicentre Age Gap study included 529 women (age, ≥ 70 years) with oestrogen receptor-positive early breast cancer who received AIs, either as primary or adjuvant treatment, at five hospitals in the UK. Researchers collected comprehensive data including the type of endocrine therapy, DEXA scan results, bisphosphonate usage, calcium and vitamin D supplementation, and the incidence of fractures during or after AI therapy. Frailty was assessed using a modified Rockwood Frailty Index, with scores being calculated across 75 variables to categorise patients as robust (< 0.08), prefrail (0.08-0.25), or frail (> 0.25). TAKEAWAY: Overall, 67% of patients had baseline DEXA scans. Of these, 42% were osteopenic and 18% osteoporotic. Scans were more common in 70- to 79-year-olds than in those aged 80 years or older and in women undergoing surgery than in those undergoing primary endocrine therapy, with marked variation across centres (P < .001 for all). Among patients receiving AI therapy, 43% were prescribed bisphosphonates, especially those who had surgery (hazard ratio [HR], 1.36; P = .04) and those aged 70-79 years (HR, 1.31; P = .02); 33% had vitamin D plus calcium along with bisphosphonates. During follow-up, 23% of patients had fractures, with significant variation across centres (P = .02), and 38% of these patients had received prior bisphosphonates. Although 94% of patients were frail or prefrail, frailty did not correlate with baseline hip (P = .10) or spine (P = .89) T scores. Bisphosphonates plus AIs were prescribed in 70% of non-frail participants vs 43% of prefrail and 47% of frail participants (P = .02). IN PRACTICE: "Patient's age and general health influence bone health decision making, with older and frailer patients often receiving non-standard care. Despite national and international recommendations, there is still wide variation in bone health management, highlighting the need for further education and standardised bone health care in older women with breast cancer," the authors wrote. SOURCE: This study was led by Elisavet Theodoulou, University of Sheffield, Sheffield, England. It was published online on July 18, 2025, in the Journal of Geriatric Oncology. LIMITATIONS: The study's inclusion of only five hospital sites limited the ability to draw broader conclusions about bone health management practices across a wider range of centres. Additionally, the interpretation of the results was complicated by the introduction of adjuvant bisphosphonates during the study period, making the cohort unstable in terms of bisphosphonate usage indications. DISCLOSURES: The Age Gap study was supported by the National Institute for Health and Care Research Programme Grants for Applied Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Low Vitamin D May Raise COVID-19 Hospitalisation Risk
TOPLINE: An analysis of over 150,000 participants found that insufficient and deficient levels of vitamin D were associated with an increased risk for COVID-19 hospitalisation but not with the risk for COVID-19 infection; however, no significant associations were found among participants with a prior cancer diagnosis. METHODOLOGY: Researchers in London used data from the UK Biobank cohort to assess the association between levels of vitamin D (insufficient and deficient vs normal) and both COVID-19 infection and hospitalisation. They included a total of 151,543 participants (mean age, 56 years; 53% women), with a subset of 24,400 participants diagnosed with cancer prior to 2019. Serum vitamin D levels were measured at baseline between 2006 and 2010 (deficiency, < 24 nmol/L; insufficiency, 25-50 nmol/L; and normal, > 50 nmol/L); all had at least one positive COVID-19 polymerase chain reaction test. Endpoints were first COVID-19 infection (measured using the positive polymerase chain reaction test result) and COVID-19 hospitalisation (measured using hospital admission records). TAKEAWAY: Among overall participants, 14% had at least one positive COVID-19 test result, of whom 11% were hospitalised; in the cancer cohort, 11% of participants tested positive for COVID-19 and 14% of them were hospitalised. Vitamin D insufficiency and deficiency were associated with 19% and 36% higher odds of COVID-19 hospitalisation, respectively, than normal levels of vitamin D (P < .001 for both); however, no association was found between low levels of vitamin D and COVID-19 infection. Sensitivity analyses showed that among Black and Asian participants, low levels of vitamin D were linked to an increased risk for COVID-19 infection but not to increased hospitalisation rates. Among the subset of patients with cancer, levels of vitamin D were not significantly associated with COVID-19 outcomes. IN PRACTICE: "[The study] results highlight the complex role of VitD [vitamin D] in COVID-19 outcomes and the varying impact it has across different population subgroups," the authors wrote. SOURCE: This study was led by Maria J. Monroy-Iglesias, Transforming Outcomes through Research, Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, England. It was published online on July 18, 2025, in PLoS One. LIMITATIONS: Vitamin D levels were measured at baseline (between 2006 and 2010) over a decade before the COVID-19 pandemic, which may have led to the misclassification of participants' vitamin D status. This study could not account for seasonal variations in vitamin D levels. Subgroup analyses were limited by small sample sizes. The study cohort was not fully representative of the UK population, and potential bias may have arisen from differential access to COVID-19 testing. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
